Windtree Therapeutics Announces Material Agreements & Officer Changes
Ticker: WINTW · Form: 8-K · Filed: Jun 27, 2025 · CIK: 946486
| Field | Detail |
|---|---|
| Company | Windtree Therapeutics Inc /De/ (WINTW) |
| Form Type | 8-K |
| Filed Date | Jun 27, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, officer-changes, equity-sale
Related Tickers: WINT
TL;DR
Windtree Therapeutics (WINT) filed an 8-K detailing new deals, terminated agreements, and exec changes. Big moves happening.
AI Summary
On June 24, 2025, Windtree Therapeutics, Inc. entered into a material definitive agreement and also terminated a material definitive agreement. The company also reported on unregistered sales of equity securities and changes in directors and officers, including compensatory arrangements. The filing also includes financial statements and exhibits.
Why It Matters
This 8-K filing indicates significant corporate actions, including new agreements, terminations, and personnel changes, which could impact the company's strategic direction and financial performance.
Risk Assessment
Risk Level: medium — The filing involves material definitive agreements, unregistered equity sales, and changes in officers, suggesting significant operational and financial shifts that carry inherent risks.
Key Players & Entities
- Windtree Therapeutics, Inc. (company) — Registrant
- June 24, 2025 (date) — Date of earliest event reported
- 2600 Kelly Road, Suite 100, Warrington, PA 18976 (address) — Company Business and Mail Address
- 2154889300 (phone_number) — Company Business Phone
FAQ
What were the specific material definitive agreements entered into by Windtree Therapeutics?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the summary text.
What was the nature of the material definitive agreement that was terminated?
The filing states that a material definitive agreement was terminated, but the specific nature of this agreement is not detailed in the provided text.
What type of equity securities were sold under the unregistered sales of equity securities?
The filing mentions unregistered sales of equity securities, but the specific type of securities is not specified in the provided text.
Were there any departures of directors or certain officers reported?
Yes, the filing indicates the departure of directors or certain officers, along with the election of directors and appointment of certain officers.
What is the fiscal year end for Windtree Therapeutics?
The fiscal year end for Windtree Therapeutics is December 31.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 27, 2025 regarding WINDTREE THERAPEUTICS INC /DE/ (WINTW).